Skip to content
Cancidas, Cancidas (previously caspofungin msd)(caspofungin)
Cancidas (caspofungin) is a small molecule pharmaceutical. Caspofungin was first approved as Cancidas on 2001-01-26. It is used to treat aspergillosis, candidemia, and mycoses in the USA. It has been approved in Europe to treat aspergillosis and candidiasis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Cancidas (generic drugs available since 2017-09-29)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Caspofungin acetate
Tradename
Company
Number
Date
Products
CASPOFUNGIN ACETATEFresenius KabiN-206110 RX2016-12-30
2 products
CANCIDASMerck KGaAN-021227 RX2001-01-26
2 products, RLD, RS
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
aspergillosisEFO_0007157D001228B44
candidemiaEFO_1001282D058387
mycosesD009181B35-B49
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Caspofungin Acetate, Caspofungin Acetate, Fresenius Kabi Usa
96364072032-12-21DP
ATC Codes
J: Antiinfectives for systemic use
J02: Antimycotics for systemic use
J02A: Antimycotics for systemic use
J02AX: Other antimycotics for systemic use in atc
J02AX04: Caspofungin
HCPCS
Code
Description
J0637
Injection, caspofungin acetate, 5 mg
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181B35-B497101220
Invasive candidiasisD058365EFO_1001283B374419
CandidemiaD058387EFO_10012821416
Invasive pulmonary aspergillosisD055744B44.013216
Liver transplantationD016031EFO_00106821113
Critical illnessD016638123
Pneumocystis pneumoniaD011020EFO_0007448B59112
Hematologic neoplasmsD01933711
Invasive hydatidiform moleD002820D39.211
Liver diseasesD008107EFO_0001421K70-K7711
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CandidiasisD002177B3745211
FungemiaD016469B49224
NeutropeniaD009503D701214
NeoplasmsD009369C80213
Myeloid leukemia acuteD015470C92.01112
LeukemiaD007938C95112
Oral candidiasisD002180EFO_0007406B37.0112
Intraabdominal infectionsD05941311
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.011
Monocytic leukemia acuteD00794811
Show 3 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544134
AspergillosisD001228EFO_0007157B44314
Hiv infectionsD015658EFO_0000764B20112
Hematopoietic stem cell transplantationD01838011
FeverD005334HP_0001945R50.911
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Invasive fungal infectionsD00007274233
Septic shockD012772A48.311
ShockD012769R57.111
FusariosisD060585EFO_100179511
SarcomaD01250911
LymphomaD008223C85.911
NeuroblastomaD009447EFO_000062111
Kidney neoplasmsD007680EFO_0003865C6411
Hot flashesD01958411
PharmacokineticsD01059911
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCASPOFUNGIN
INNcaspofungin
Description
Caspofungin (INN; brand name Cancidas) is a lipopeptide antifungal drug from Merck & Co., Inc. discovered by James Balkovec, Regina Black and Frances A. Bouffard. It is a member of a new class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin was the first inhibitor of fungal (1→3)-β-D-glucan synthesis to be approved by the United States Food and Drug Administration. Caspofungin is administered intravenously.
Classification
Small molecule
Drug classantifungal antibiotics (undefined group)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O
Identifiers
PDB
CAS-ID162808-62-0
RxCUI
ChEMBL IDCHEMBL499808
ChEBI ID474180
PubChem CID468682
DrugBankDB00520
UNII IDF0XDI6ZL63 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Cancidas - Merck Sharp & Dohme
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 10,228 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
17 adverse events reported
View more details